Vascular Therapies is a biotechnology company focused on improving patient outcomes by reducing surgical stenosis in patients with kidney and vascular disease. The company has developed Sirogen™, an investigational sirolimus formulation for local, perivascular drug delivery. Sirogen™ is currently undergoing clinical trials to determine its safety and effectiveness in improving vascular access outcomes in patients requiring an arteriovenous fistula for hemodialysis.
Location: United States, New Jersey, Cresskill
Employees: 1-10
Total raised: $49M
Founded date: 2001
Investors 2
| Date | Name | Website |
| - | New Scienc... | newscience... |
| - | Savitr Cap... | savitrcapi... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 30.03.2022 | - | $25M | - |
| 03.03.2022 | - | $24M | - |
Mentions in press and media 3
| Date | Title | Description |
| 30.03.2022 | Vascular Therapies Closes $25M Financing | Vascular Therapies, a Cresskill, NJ-based clinical-stage biopharma company, raised $25M in funding. The financing is comprised of existing and new investors, including a Fortune 100 global healthcare company. The company intends to use the ... |
| 19.02.2015 | Vascular Therapies raises $16.2M for hemodialysis transplant work | It last raised funds – a $5 million Series E round – in 2011. But this most recent equity round is pretty impressive for such a low-profile startup. A call to CEO Sriram Iyer has yet to be returned – but stay tuned for more. Promoted This P... |
| - | Vascular Therapies raises $16.2M for hemodialysis transplant work | New Jersey medical device maker Vascular Therapies just raised $16.2 million of a potential $27 million, according to a regulatory filing. The funding comes from 30 investors. The company’s kept fairly low profile – it was launched in 2001,... |